Literature DB >> 17709403

LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA).

Liana C Chan1, Wendy Peters, Yan Xu, Jerold Chun, Robert V Farese, Sylvaine Cases.   

Abstract

Increasing evidence supports roles for lipids in the biology of immune cells. In particular, bioactive lipids such as sphingosine-1-phosphate (S1P) bind to cognate G protein-coupled receptors (GPCRs) and modulate leukocyte trafficking and homeostasis. Lysophosphatidic acid (LPA) represents a family of bioactive lipids, which differ in the length and degree of saturation of the fatty acyl chain. LPA is structurally related to S1P and exerts cellular effects by binding to five known GPCRs (LPA(1-5)). Its function in the immune system is less clear, although it was shown to induce chemotaxis of human dendritic cells (DCs) and activated T cells. In this study, we show that LPA can induce chemotaxis of immature but not mature mouse DCs and that only unsaturated and not saturated LPA species are efficient chemoattractants. However, both LPA species do not alter DC maturation or chemotaxis to other chemokines. The loss of DC migration capability correlated with the down-regulation of expression of the receptors LPA(3) and LPA(5), and expression of LPA(1), LPA(2), and LPA(4) did not change. A LPA(3) antagonist reduced immature DC migration to LPA by 70%, suggesting that LPA(3) mediates immature DC chemotaxis to unsaturated species of LPA. Furthermore, isolated, immature DCs from mice lacking LPA(3) exhibited a 50% reduction in migration to LPA. In summary, our results indicate that immature mouse DCs migrate preferentially in response to unsaturated LPA and that LPA(3) is important in this response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709403     DOI: 10.1189/jlb.0407221

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  39 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 2.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 3.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 4.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  Allergic to autotaxin. A new role for lysophospholipase d and lysophosphatidic Acid in asthma?

Authors:  Steve N Georas
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

6.  Effect of lysophosphatidic acid on the immune inflammatory response and the connexin 43 protein in myocardial infarction.

Authors:  Duoduo Zhang; Yan Zhang; Chunyan Zhao; Wenjie Zhang; Guoguang Shao; Hong Zhang
Journal:  Exp Ther Med       Date:  2016-03-09       Impact factor: 2.447

7.  Lpa2 is a negative regulator of both dendritic cell activation and murine models of allergic lung inflammation.

Authors:  Jason Emo; Nida Meednu; Timothy J Chapman; Fariba Rezaee; Marlene Balys; Troy Randall; Tirumalai Rangasamy; Steve N Georas
Journal:  J Immunol       Date:  2012-03-16       Impact factor: 5.422

Review 8.  Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity.

Authors:  Steve N Georas
Journal:  Immunol Res       Date:  2009-01-30       Impact factor: 2.829

Review 9.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 10.  Therapeutic potential of autotaxin/lysophospholipase d inhibitors.

Authors:  Lorenzo Federico; Zehra Pamuklar; Susan S Smyth; Andrew J Morris
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.